HC Wainwright Issues Optimistic Forecast for ANIX Earnings

Anixa Biosciences, Inc. (NASDAQ:ANIX) – Analysts at HC Wainwright raised their Q1 2025 earnings estimates for shares of Anixa Biosciences in a research report issued to clients and investors on Tuesday, February 18th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.10) per share for the quarter, up from their previous estimate of ($0.11). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Anixa Biosciences’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Anixa Biosciences’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.41) EPS.

Separately, D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday, January 22nd.

Anixa Biosciences Stock Down 2.8 %

Shares of NASDAQ ANIX opened at $3.08 on Friday. The firm’s 50-day simple moving average is $2.71 and its 200 day simple moving average is $3.05. The company has a market cap of $99.17 million, a price-to-earnings ratio of -7.90 and a beta of 0.93. Anixa Biosciences has a 12-month low of $2.07 and a 12-month high of $4.20.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Friday, January 10th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02.

Insiders Place Their Bets

In other Anixa Biosciences news, CEO Amit Kumar bought 43,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was acquired at an average cost of $2.23 per share, with a total value of $95,890.00. Following the purchase, the chief executive officer now owns 559,925 shares in the company, valued at $1,248,632.75. This trade represents a 8.32 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Lewis H. Titterton, Jr. bought 10,000 shares of the stock in a transaction that occurred on Friday, January 17th. The shares were acquired at an average cost of $2.57 per share, with a total value of $25,700.00. Following the completion of the purchase, the director now owns 922,334 shares in the company, valued at $2,370,398.38. This represents a 1.10 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders bought 75,289 shares of company stock valued at $177,021. 25.30% of the stock is currently owned by insiders.

Institutional Trading of Anixa Biosciences

A number of large investors have recently bought and sold shares of the business. Focus Partners Wealth bought a new stake in Anixa Biosciences during the 4th quarter worth approximately $162,000. LPL Financial LLC boosted its position in Anixa Biosciences by 37.2% during the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock worth $100,000 after acquiring an additional 11,633 shares during the last quarter. Tyler Stone Wealth Management boosted its position in Anixa Biosciences by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after acquiring an additional 21,008 shares during the last quarter. International Assets Investment Management LLC boosted its position in Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after acquiring an additional 23,800 shares during the last quarter. Finally, Westside Investment Management Inc. boosted its position in Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after acquiring an additional 21,100 shares during the last quarter. 29.13% of the stock is owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.